Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an in vitro model of pulmonary fibrosis - Amsterdam 2025

Pulmonary arterial hypertension: risk assessment and impact of current and newly developed treatments

Chair(s): Laurent Savale, Jurjan Aman

Session type: Poster session

Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an in vitro model of pulmonary fibrosis

Zhaoqing Ding

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Risk Improvements in Ralinepag Open-Label Extension

Colin Church

Poster

Abstract

?CT Analysis of Microvascular Hemodynamics in PAH

Gitte Aerts

Poster

Abstract

Partial remission induction in pulmonary arterial hypertension and its predictors

Keiichiro Kuronuma

Poster

Abstract

Prognostic value of right ventricular myocardial work in patients with pulmonary arterial hypertension

Simon Valentin

Poster

Abstract

Cardiopulmonary exercise testing responses to treatment in patients with pulmonary arterial hypertension and cardiopulmonary comorbidities

Andrea Baccelli

Poster

Abstract

Dose rationale for UNISUS, an ongoing, event-driven, phase III superiority study evaluating macitentan 75mg vs 10mg in pulmonary arterial hypertension (PAH)

Dénes Csonka

Poster

Abstract

Five-year survival in Pulmonary Hypertension patients: risk stratification by a machine learning approach.

Maria Pia Claudia Varlese

Poster

Abstract

Impact of dynapenia on the prognosis of patients at high risk of pulmonary hypertension.

Carlos Patricio Chávez Guzmán

Poster

Abstract

Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an in vitro model of pulmonary fibrosis

Zhaoqing Ding

Poster

Abstract

Real-world clinical outcomes according to individualised selexipag dose in pulmonary arterial hypertension (PAH)

Tobias Lange

Poster

Abstract

A longitudinal study of digital walk tests in the community: patient-centred measures of activity in patients with pulmonary hypertension.

Joseph Newman

Poster

Abstract

Tissue and peripheral oxygen saturation during maximal exercise in pulmonary hypertension

Carolina Dorigon

Poster

Abstract

Evaluating the Prognostic Accuracy of ESC/ERS Risk Stratification Models in Pulmonary Arterial Hypertension Patients in Saudi Arabia

Abdullah Alharbi

Poster

Abstract

Risk assessment in Pulmonary Arterial Hypertension: comorbidities impact

Albert Riudor Guri

Poster

Abstract

Long-term efficacy and safety of rehabilitation in stable PAH patients: results from the FONCE-HTAP trial

Laurent Bertoletti

Poster

Abstract

Seralutinib increases small pulmonary artery vessel volume and reduces vessel wall remodeling: Insights from AI-driven CT imaging analysis

Raul San Jose Estepar

Poster

Abstract

Sotatercept in pulmonary arterial hypertension (PAH): long-term follow-up in SOTERIA

Ioana R Preston

Poster

Abstract

Usefulness of Risk Stratification in the 2022 ESC/ERS Guidelines for group 3 Pulmonary Hypertension

Keiko Yamamoto

Poster

Abstract

Assessment of Pulmonary Arterial Hypertension management at the time of death: a comparative study between France and the UK

Athénaïs Boucly

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}